By Steve Usdin
Contributing Editor

WASHINGTON - Rep. Ron Wyden has injected himself into the negotiations between the NIH and Myriad Genetics Inc. over the ownership of the BRCA1 breast cancer gene, declaring his continuing interest in the "leverage" that the NIH or other federal agencies can use to lower prices on new drugs or devices.